tradingkey.logo

BRIEF-LB Pharmaceuticals Positive Topline Results From Phase 2 Trial Of Lb-102 In Schizophrenia

ReutersJan 8, 2025 12:19 PM

- Lb Pharmaceuticals:

  • LB PHARMACEUTICALS: POSITIVE TOPLINE RESULTS FROM PHASE 2 TRIAL OF LB-102 IN SCHIZOPHRENIA

  • LB PHARMACEUTICALS: TRIAL MET PRIMARY ENDPOINT WITH STATISTICALLY SIGNIFICANT REDUCTION IN PANSS TOTAL SCORE AT ALL DOSE LEVELS VERSUS PLACEBO

  • LB PHARMACEUTICALS: LB-102 WAS GENERALLY SAFE & WELL-TOLERATED

  • LB PHARMACEUTICALS: TO INITIATE PHASE 3 DEVELOPMENT PROGRAM LATE THIS YEAR OR EARLY NEXT YEAR

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI